A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2013
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
Epistemonikos ID: e4114b634cd5fce3d3c80a4c8e79af0fa404d5e5
First added on: Feb 15, 2022